Mesenchymal Stem Cells (MSCs) migrate specifically to tumors in vivo, and coupled with their capacity to bypass immune surveillance, are attractive vehicles for tumor-targeted delivery of therapeutic agents. This study aimed to introduce MSC-mediated expression of the sodium iodide symporter (NIS) for imaging and therapy of breast cancer. Tumor bearing animals received an intravenous or intratumoral injection of NIS expressing MSCs (MSC-NIS), followed by 99m Technetium pertechnetate imaging 3-14 days later using a BazookaSPECT c-camera. Tissue was harvested for analysis of human NIS (hNIS) expression by relative quantitative-polymerase chain reaction. Therapy animals received an i.p. injection of 131
INTRODUCTION
Mesenchymal stem cells (MSCs) are nonhematopoietic multipotent cells that can be isolated and expanded with relative ease from a number of different sources, including bone marrow and adipose tissue [1, 2] . They are defined by a panel of specific cell surface antigens [3] , and an innate ability to differentiate along multiple lineages including osteogenic, chondrogenic, and adipogenic lineages [4] . Although MSCs play a primary role in tissue regeneration [5, 6] , they also have the proven ability to migrate specifically to the site of multiple tumor types in vivo [7, 8] . When combined with their capacity to bypass host immune surveillance [9, 10] , this makes MSCs attractive vehicles for tumor-targeted delivery of therapeutic agents and their biological products, with promising results reported in a range of tumor types [8, 11] . This is particularly promising for metastatic disease, as the majority of cancer-related deaths occur as a result of complications of metastasis. In the case of breast cancer, the Author contributions: R.M.D.: conception and design, financial support, collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; J.R.: collection and/or assembly of data, data analysis and interpretation; R.J.H.: collection and/or assembly of data, data analysis and interpretation, final approval of manuscript; J.C.M.: provision of study material, data analysis and interpretation, final approval of manuscript; B.W.M. and R.F: data analysis and interpretation; Z.L.: data analysis and interpretation, final approval of manuscript; C. O'F.: conception and design; M.J.F.: conception and design, final approval of manuscript; H.H.B.: conception and design, data analysis and interpretation, final approval of manuscript; J.M.M. and F.P.B.: conception and design, provision of study material, data analysis and interpretation; T.O'B.: conception and design, provision of study material, data analysis and interpretation, final approval of manuscript; M.J.K.: conception and design, financial support, data analysis and interpretation, final approval of manuscript. overall mortality rate in women is second to lung cancer, with more than 39,000 deaths anticipated in the U.S. in 2010 [12] . In this context, previous studies have demonstrated targeted MSC-mediated delivery of conditionally replicating adenovirus [13] or interferon-b [14] to lung metastases of breast cancer in vivo, showing a significant therapeutic effect. We have also reported previously the engraftment of MSCs in nodal metastases of breast cancer in vivo [15] . One of the major challenges to this approach is lack of understanding of MSCtumor tropism, and the potential for nonspecific targeting of healthy tissue. The ability to dynamically image MSC migration and engraftment in real time to confirm tumor targeting is essential to increase understanding of this process and provide for translation to the clinical setting.
The ability of the thyroid gland to concentrate iodide is based on expression of the sodium iodide symporter (NIS) and forms the basis for radiolabeled iodide imaging and treatment of thyroid disease. A major advantage to the approach is the ability to noninvasively image uptake of a tracer such as 99m Technetium pertechnetate ( 99m TcO À 4 ) or 123 Iodide ( 123 I) before administration of a therapeutic dose of 131 I. Because of safety and efficacy of this approach in imaging and treatment of thyroid disease [16] , there have been a number of studies reporting successful introduction of ectopic NIS expression to support imaging and therapy of nonthyroidal malignancies [17, 18] . However, the major limitation of current NIS delivery and gene therapy in general is lack of tumor targeting. A potential way to overcome this is through the use of MSCs as cellular vehicles. NIS-transduced MSCs could potentially provide for noninvasive imaging to track MSC homing and engraftment at the tumor site. Because of the path length of 131 I, successful engraftment of NIS-expressing MSCs may potentially also provide for ablation of surrounding tumor cells mediated by the bystander effect of the radionuclide [19] .
To date, the majority of MSC biodistribution studies have relied on invasive techniques such as tissue biopsy followed by immunohistochemistry or polymerase chain reaction (PCR). In the case of NIS, as opposed to direct cell labeling, functional uptake of tracer is dependent on cell viability, and NIS itself is a nontoxic, nonimmunogenic protein. There have been a number of studies tracking MSC migration to tumors in vivo, using expression of a reporter gene in conjunction with bioluminescent or Positron Emission Tomography (PET) imaging [20] [21] [22] [23] [24] . Recently, NIS has been used as a reporter gene in neural [25] [26] [27] , cardiac [28] , hematopoietic [29] , and MSCs [25] . Although these studies support the feasibility of this approach, the significant advantage of NIS having the potential to serve both as a reporter and as a therapeutic gene has yet to be exploited.
The aim of this study was to introduce functional NIS expression into MSCs and determine whether systemic administration to tumor bearing animals would result in sufficient engraftment to permit radionuclide imaging. After functional imaging, the feasibility of radioiodide therapy of tumors based on the bystander effect from NIS-expressing MSCs was also investigated.
MATERIALS AND METHODS

Isolation and Culture of MSCs
MSCs were isolated from bone marrow aspirates of healthy volunteers with informed consent by direct plating using a defined clinical protocol. Cells were cultured for 12-15 days to deplete the nonadherent hematopoietic cell fraction and maintained in alpha modified Eagle's medium supplemented with preselected FBS (10%) and 100 IU/ml penicillin per 100 lg/ml streptomycin. The ability of MSCs to differentiate into chondrocytes, adipocytes, and osteoblasts was confirmed before use. Characterization of surface receptors was performed targeting the markers CD105, CD73, and CD90 (positive) as well as CD34 and CD45 (negative).
Adenoviral Infection of MSCs
A replication-deficient human recombinant adenovirus serotype 5 construct containing human NIS (hNIS) under the control of the cytomegalovirus (CMV) promoter (AdNIS) was used [30] . MSCs suspended in serum-free medium were centrifuged in the presence of virus for 90 minutes at 2,000g. After infection, the pellet of cells was rinsed in serum free medium and resuspended in complete medium for culture as required. Transduction efficiency was determined using the Green Fluorescent Protein (GFP) reporter gene. GFP expression was visualized 48 hours after infection with Ad5/CMV/GFP (Vector Biolabs, Philadelphia, PA, www.vectorbiolabs.com) using fluorescence microscopy (Olympus BX60, Hamburg, Germany, www.olympus-europa.com) and quantified by flow cytometry using a Guava EasyCyte 8HT (Millipore, Billerica, MA), www.millipore.com flow cytometer.
Detection of NIS Expression
At a variety of time points (3-28 days) after infection with adenovirus (multiplicity of infection [MOI] 0-200), total RNA was extracted from cells using the RNeasy Mini Kit (QIAGEN Ltd., Valencia, CA, www.qiagen.com) following manufacturer's protocol. RNA (1 lg) was reverse transcribed using SuperScript III reverse transcription enzyme (Invitrogen, Carlsbad, CA, www.invitrogen.com). cDNA samples were amplified and analyzed by relative quantitative-PCR (RQ-PCR) using the ABI Prism 7000 sequence detector system (Applied Biosystems, Carlsbad, CA, www.appliedbiosystems.com). PreDeveloped Taqman Assay Reagents (PDARs) specific to hNIS (Solute Carrier 5, member 5; SLC5A5) and the endogenous control peptidyl-prolyl isomerase A (PPIA) were used. The comparative C T method was used to quantify expression of hNIS normalized to PPIA, with the levels expressed relative to untransfected cells. Changes in NIS expression were expressed using the 2 ÀDDCT method [31] and the fold change in triplicate experiments was recorded and presented as mean 6 SEM.
To detect protein expression, adenovirus-infected or control cells were plated into two-chamber slides. After 3 days, slides were put on ice for 15 minutes, and cells were fixed in ice cold methanol at À20 C for 15 minutes. NIS protein expression and localization was detected by immunohistochemistry using a monoclonal antibody [32] and a Discovery RedMAP Kit on a Discovery Ventana system (Tucson, AZ, www.ventanadiscovery.com). Slides were then washed in warm soapy water to remove oil, followed by rinsing in ddH 2 0 and sequential treatment as follows: 3 minutes in 75% alcohol, 3 minutes in 95% alcohol, 3 minutes in 100% alcohol, and two serial immersions of 3 minutes in Xylene. The slides were then mounted in Di-n-butyl Phthalate in Xylene (DPX) mounting medium and analyzed using an Olympus BX60 microscope and analySIS Soft Imaging System.
I Uptake Studies
The ability of MSCs to concentrate iodide at various time points (1-7 days) after adenovirus infection was determined as previously described [33] . Briefly, after transfection, cells were incubated in Hank's Buffered Salt Solution (HBSS) containing 10 mmol/l HEPES, 10 lmol/l NaI, and 0.1 lCi Na 125 I/ml (pH 7.3), and 10 lmol/l KClO 4 , a competitive inhibitor of iodide uptake by NIS, was included in control wells. After 45 minutes incubation at 37 C, cells were washed with ice-cold Phosphate Buffered Saline (PBS), lysed with 1 mol/l NaOH, and concentrated iodide measured on a c-counter. 6 AdNIS infected MSCs suspended in 50 ll Dulbecco's modified Eagle's medium ( Fig. 1 ). For i.t. injection, the needle tip was inserted and then retracted as the cells were injected, followed by repositioning in another area of the tumor to increase cell dispersal. These groups were subdivided into a therapy study and a biodistribution study. A further two groups of animals (n ¼ 6 each) received either no MSC injection, or an i.v. injection of naked AdNIS (no MSCs). Seven days before administration of radionuclide ( 99m TcO À 4 or 131 I), animals were placed on a low-iodine diet with thyroxine (T 4 )-supplemented water (5 mg/l) to reduce thyroidal uptake of radionuclides (Fig. 1) . All animal experiments were licensed and carried out according to the guidelines of the Institutional Animal Ethics Committee. Experiments involving radionuclides were approved by the Radiological Protection Institute of Ireland and performed according to institutional guidelines. Fig. 1 ). After 1 hour, animals were anesthetized with a ketamine/xylazine cocktail and images acquired using a BazookaSPECT c-camera [34] .The BazookaSPECT system consists of a 1-mm pinhole collimator, a 600-lm Hamamatsu caesium iodide (CsI) scintillator, an image intensifier, an optical system, and a charge-coupled device camera. A rotating platform supported capture of SPECT data, with a total of 30 images acquired in 12 steps over a full rotation. Planar imaging was also performed with an acquisition time of 15 minutes. Data were acquired using a LabView interface (National Instruments) and stored using a list-mode method. The volume data were reconstructed using 0.5-2.0 mm voxels. The dose of tracer accumulated at each site was estimated and expressed as a percentage of the total administered dose. Regions of interest (ROIs) were drawn around all visible organs and the whole body. After correction for background activity, the level of uptake in each area was expressed as a percentage of the total activity in the mouse.
Tumor Growth and MSC Administration
In Vivo Biodistribution of NIS-Expressing MSCs
Gene Expression. Approximately 3 and 7 days after administration of MSC-NIS or naked virus (AdNIS) to tumor bearing animals, mice were sacrificed by CO 2 inhalation and organs harvested for analysis by RQ-PCR. The following organs were retrieved: heart, lungs, liver, spleen, kidneys, stomach, large/small intestine, and tumor. Tissues were immediately immersed in RNA later (Ambion Inc., Austin, TX, www.ambion.com), and then stored at À80 C until required. Before RNA extraction, tissue was homogenized briefly in 1 ml TRIzol Reagent (Invitrogen, Carlsbad, CA, www.invitrogen.com) using a Polytron PT 1600 E at 30,000 rpm. RNA was extracted and analyzed by RQ-PCR as described for cultured cells. Targets included NIS (human and mouse specific PDARs), human MRPL19 (endogenous control for human cells), and mouse b-actin (endogenous control for mouse cells). 
In Vivo
Histology and Immunohistochemistry
Approximately 8 weeks after administration of 131 I or saline, animals were sacrificed by CO 2 inhalation and tumors were harvested. Tissue was immersed in 4% paraformaldehyde for 24 hours, transferred to 30% sucrose for 24 hours, snap frozen in an isopentane/liquid nitrogen bath, and stored at À80 C until required for cryosectioning. Frozen tissue samples from xenografts were cryosectioned (5 lm sections) and allowed to air dry at room temperature followed by rehydration in PBS-0.05% Tween-20. Sections were then stained with H&E or prepared for immunohistochemistry as described. After blocking of endogenous peroxidases, antigen retrieval was performed using citrate buffer. Sections were probed with a polyclonal antibody to proliferating cell nuclear antigen (PCNA; AbCAM). A HRP-conjugated secondary antibody was used followed by detection using a peroxidase substrate kit containing the chromogen diaminobenzidine (Burlingame, CA, www.vectorlabs.com). Cells were counterstained with H&E. Once staining was complete, sections were washed in warm soapy water, dehydrated in serial alcohol immersions, and mounted using DPX mounting medium.
RESULTS
In Vitro NIS Expression and Function After Adenovirus Infection of MSCs
Adenovirus containing GFP was used to determine transduction efficiency and optimize viral infection conditions. Visualization of cells from two individual donors using a fluorescent microscope revealed that the majority of the cell populations were strongly positive for GFP after transfection ( Fig. 2A (i) , (ii)). Quantification of GFP positive cells by flow cytometry demonstrated a transduction efficiency of 85%-92% at an MOI of 100, with no significant benefit gained from increasing the MOI to 200.
NIS gene expression in MSCs 72 hours after adenovirus infection was confirmed at a MOI of 50-200 using RQ-PCR (Fig. 2B) . Robust gene expression was detected with a mean 3.9 log fold increase over uninfected cells at MOI 100.
The ability of transduced MSCs to concentrate iodide ( 125 I) was determined at a variety of time points (1-7 days) after infection at a range of MOIs (Fig. 2C) . Iodide uptake studies revealed efficient NIS function, with a 27-to 60-fold increase in uptake at MOIs ranging from 50 to 200. Inclusion of the NIS inhibitor perchlorate (KCLO 4 ) in wells resulted in 70%-85% inhibition of iodide uptake, confirming specificity ( 2C). NIS expression and function remained significantly elevated 7 days after infection. Further analysis of NIS gene expression at later time points after adenoviral infection revealed persistence of robust expression up to 28 days later (Fig. 2D) . There was no significant difference in NIS expression or function detected between cells infected at MOI 100 or 200, and so subsequent infections were performed at MOI 100.
In Vivo Imaging of MSC-NIS Engraftment
Approximately 3-14 days after i.v. injection of MSC-NIS, animals received an i.p. injection of 99m TcO À 4 and imaging was performed using a BazookaSPECT c-camera (Fig. 3) . In control animals that had received no injection of MSC-NIS, a pattern of uptake correlating with native NIS expression was observed, with 99m TcO À 4 concentrated in the thyroid/salivary gland and stomach (Fig. 3A) . Approximately 3 days after i.t. injection of MSC-NIS, robust uptake of tracer at the tumor site was observed (Fig. 3B) . After i.v. administration of MSC-NIS, an image of animal intestines was also observed at day 3 ( Fig. 3C) , with some diffuse uptake also seen in the chest area. A weak image of the right flank tumor was also visible (Fig. 3C) . By day 14, uptake of tracer was visible at the site of the tumor with a significant reduction in accumulation in nontarget tissue observed (Fig. 3D) . The bladder was also visible in some images as a result of tracer excretion in urine. Based on ROI readings, levels of tracer accumulation in areas of interest were expressed as a percentage of total administered dose. Levels of accumulation in the thyroid and stomach remained similar at day 3 (1% thyroid, 14.7% stomach) and day 14 (2.3% thyroid, 15.9% stomach). At day 3, 18% of tracer was accumulated in intestines and had reduced to nonsignificant levels by day 14. Accumulation at the tumor site was estimated at 1.2% on day 3 (Fig. 3C) , increasing to 9.4% by day 14 (Fig. 3D) .
RQ-PCR Detection of NIS Expression in Harvested Tissues
Approximately 3 and 7 days after i.v. injection of MSC-NIS or adenovirus alone (AdNIS), animals were sacrificed and organs were harvested for detection of NIS expression by RQ-PCR (Table 1 ). The species specific human endogenous control MPRL19 was included as an indicator for the presence of human cells (engrafted MSCs) in tissues. As expected, MRPL19 was detected in the tumors established using human cells but was not detected in any other tissue when virus alone was administered. There was no detectable hNIS expression at the tumor site, although it was detected in animal heart, lungs, and liver at day 3, but was no longer present at day 7 (Table 1) .
Approximately 3 days after administration of MSC-NIS, hNIS was detected in tumor, heart, lungs, liver, and large intestine tissue. Excluding liver, MRPL19 was also detected in these tissues, indicating the presence of engrafted human MSCs. In the case of liver tissue, no MRPL19 was detected suggesting that NIS expression was due to free virus and not MSC engraftment. In line with this, NIS was no longer detected in liver tissue at day 7. Although expression of NIS/ MRPL19 was depleted by day 7 in heart, lungs, and liver, the level was maintained at the tumor site (Table 1) .
In Vivo 131 I Therapy
Animals received an i.p. injection of 1 mCi/37 MBq 131 I or saline, 14 days after i.t. or i.v. injection of MSC-NIS. In control animals, (no MSC injection) and those that received MSC-NIS i.v. without 131 I therapy, tumor volume continued to increase rapidly throughout the 8 weeks of monitoring, with no significant difference in volume detected between the two groups (Fig. 4) . In animals that received i.t. injections of MSC-NIS followed by saline or 131 I, there was an apparent reduction in the rate of tumor growth from the 3rd week (5 weeks after MSC injection), although no significant difference in tumor volume between treated (mean 6 SEM, 473 6 80 mm 3 ) and untreated (391 6 124 mm 3 ) animals was detected. The greatest impact of intervention was observed in animals that received an i.v. injection of MSC-NIS followed by 131 I 14 days later, which resulted in a significant reduction in tumor growth rate and final volume (236 6 62 mm 3 ) when compared with control animals (i.v. MSC-NIS þ saline, 953 6 189 mm 3 ).
Histology and Immunohistochemistry
H&E staining revealed extensive necrotic areas in tumors harvested from animals that received 131 I therapy 14 days after MSC-NIS delivery, but not control tumors (Fig. 5A (i)-(iv) ). This was observed irrespective of the route of MSC-NIS delivery, with an example of control and treated tumors after i.v. (Fig. 5A (i), (ii) ) or i.t. (Fig. 5A (iii), (iv) ) delivery of MSC-NIS shown. Areas of necrosis in tissue from treated animals were quantified at 20%-80% (range) of total section area. Further analysis of tissue sections using a monoclonal antibody targeting the proliferative marker PCNA was also performed. In support of H&E findings, in tumors from control animals (no 131 I treatment), most cell nuclei were positive for PCNA, indicating the presence of actively proliferating cells (Fig. 5B (i), (iii) ). In contrast, tumors from treated animals stained weakly for PCNA (Fig. 5B (ii), (iv) ).
DISCUSSION
This study describes the use of MSCs as cellular vehicles for breast tumor-targeted delivery of NIS, supporting dynamic radionuclide imaging and therapy of the disease. Correct posttranslational targeting of NIS to the cell membrane is required for function, and concentrated iodide must be retained within the cell long enough to be therapeutically effective [35] . The results presented demonstrate membrane targeted and functional NIS expression after adenoviral infection of MSCs. It is noteworthy that NIS function was found to persist relatively long-term in vitro, with robust iodide uptake still detected 7 days after infection. As adenovirus-mediated gene expression is transient, peak expression is usually detected within 3-5 days after infection [36] [37] [38] . However, in this case, gene expression was found to persist for up to 28 days and further investigation revealed that this was related to cell proliferation. MSCs undergo cell contact mediated inhibition of growth which resulted in persistent gene expression. When cells were passaged after infection, NIS expression and function decreased and were found to be inversely related to expression of the proliferative marker, Ki67 (results not shown).
In this study, investigation of MSC-NIS biodistribution following systemic infusion revealed engraftment in lungs, heart, intestine, and tumor within a few days of administration. This concurs with previous reports showing initial ectopic engraftment in nontarget tissues, particularly the lungs [20, 39] . However, at later time points, while detection of engraftment depleted elsewhere, the cells persisted at the tumor site. It is very encouraging that the level of i.v. infused MSC-NIS engraftment at the tumor site was high enough to support concentration of sufficient tracer to generate a signal over background. RQ-PCR analysis of tissues harvested following c-camera imaging supported this data, with robust hNIS expression detected at the tumor site. Although NIS expression depleted in nontarget tissues by day 7, gene expression persisted in tumor tissue. hNIS was not detected in the liver or spleen of these animals, with very low levels detected in the heart and lungs. When AdNIS was administered alone, ectopic hNIS expression was detected in multiple tissues including liver, lungs, spleen, and kidney, highlighting efficient tumor targeting of MSCs. The data further highlights the importance of tracking MSC migration in real time, and the advantage of being able to perform a pretherapy scan to confirm tumor targeted MSC-NIS engraftment before administration of 131 I. The persistent functional NIS expression at day 14 also supported in vitro observations and suggests that the cells were not actively proliferating at the tumor site. This is in agreement with a previous report by Sasportas et al. [22] , who found that MSCs persisted at the site of a glioblastoma in vivo, but did not proliferate.
Approximately 2 weeks after MSC-NIS infusion, in vivo imaging confirmed MSC engraftment and functional NIS expression at the target site, with the level of tracer in nontarget tissues significantly decreased compared to day 3. This provided grounds to proceed to 131 I therapy. In animals that received an i.v. injection of MSC-NIS without treatment, mean tumor volume was largest in the study, although not significantly different from MSC free (control) animals. In those that received i.t. MSC-NIS, tracking of tumor volume revealed no significant effect of 131 I therapy. However, further analysis of tumor tissue revealed increased apoptosis in tumors following direct injection, although to a lesser extent than that observed following i.v. MSC-NIS delivery. This may be due to the pattern of engraftment of MSCs within the tumor. We and others have previously shown that i.t. or local injection of MSCs can result in migration and engraftment predominantly around the periphery of the tumor [15, 40] . However, both i.t. groups displayed decreased tumor volume as compared to control animals, suggesting that MSC injection had a negative effect on tumor growth. This is supported by previous studies showing that injection of MSCs into tumor bearing animals resulted in inhibition of tumor growth [40] [41] [42] . In the case of i.v. administration, we had previously reported MSC engraftment throughout breast tumors, apparently lining blood vessels [15] . Beckermann et al. [43] also demonstrated migration of MSCs toward tumor vessels and interaction with the endothelium. Adipose-and bone marrowderived stem cells have also been reported to incorporate into tumor vessels and differentiate into endothelial cells [44] or pericytes [45] , respectively. In this study, i.v. MSC-NIS injection followed by 131 I therapy had a cytostatic effect causing a remarkable reduction in the rate of tumor growth, with resulting tumor volumes approximately 75% smaller than their counterpart controls. Histological analysis also revealed significant necrosis in tumor tissues harvested following i.v. MSC-NIS and therapy. Although not investigated here, this may be as a result of effective targeting of the tumor vasculature. An added safety element to this approach is that 131 I therapy will also potentially result in ablation of MSCs, reducing the potential for any negative effects of the cells at the tumor site. Further study is required to investigate persistence of MSCs following therapy and determine their fate in the tumor microenvironment. There were no adverse effects associated with administration of MSC-NIS (up to 10 weeks) or 131 I administration (up to 8 weeks) observed. These results could conceivably be further improved with a repeat dose of MSC-NIS and radioiodide, as recent studies have shown that tumor irradiation stimulates increased MSC engraftment [7, [46] [47] [48] . This may create even greater stimulus for MSC engraftment and treatment of residual disease, which would be particularly attractive in the setting of metastatic disease.
CONCLUSION
This study describes successful exploitation of the dual role of NIS as both a reporter and therapeutic gene following systemic infusion in tumor bearing animals, while using MSCs as tumor-targeted cellular vehicles. The results are extremely promising, particularly because MSCs target multiple tumor types, and so the approach has potential applications in a range of cancers. The extensive safety record of radioiodide therapy in the treatment of thyroid disease is a major advantage to the use of NIS as a therapeutic gene [16] . In the context of breast cancer, significant inhibition of thyroidal uptake of 131 I can be achieved through T 3 supplementation before and during 131 I therapy [16, 49] . A range of isotopes are efficiently transported by NIS and are readily available and approved for clinical purposes. Also, gamma camera technology is more widely accessible than more expensive PET scanners. The ability to noninvasively track MSC migration and transgene expression in real time before therapy is a major advantage to this strategy. This promising data supports the viability of this approach as a novel therapy for breast cancer.
